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ABSTRACT 
 
SYNTHESIS AND AROMATASE INHIBITION PROPERTIES OF NEW 
BORONIC ACID CHALCONE DERIVATIVES 
 
 Chalcones (1,3-diaryl-2-propen-1-ones) are one of the best known naturally 
occurring biological active compounds belonging to flavonoid family. They possess 
wide range of biological properties such as; anti-cancer, anti-bacterial, anti-
inflammatory, anti-angiogenic. In addition, chalcone boronic acid derivatives have been 
tested for their anti-cancer properties and saccharide sensors abilities in few of the 
recent studies. In those studies, it is speculated that boronic acid chalcone derivatives 
are selectively cytotoxic against cancer cells rather than healthy cells. 
 In the present study, synthesis of simple chalcones, derivatized by two boronic 
acids, and 2-naphthyl chalcones having a single boronic acid are reported first time in 
literature. For this purpose different commercially available acetylphenyl boronic acid 
and formylphenyl boronic acid derivatives are reacted in alkaline methanol to yield 
diboronic acid chalcone compounds. Similarly condensation reaction of 2-
naphthaldehyde with different acetylphenyl boronic acids yielded the monoboronic 
acids derivatized 2-naphthyl chalcones. Synthesized diboronic acid chalcone derivatives 
and 2-naphthyl calcone boronic acid derivatives were tested for their anti-cancer 
properties against human mammary adenocarcinoma cancer cell lines (MCF-7), and 
human prostate cancer cell lines (PC3). Their aromatase inhibition potentials were also 
reported first time in here. In addition, their binding capabilities upon D-fructose, D-
galactose and D-glucose of these compounds in physiologic pH were also examined. 
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ÖZET 
 
YEN BORONK AST ÇALKON TÜREVLERNN SENTEZLENMES 
VE AROMATAZ NHBSYONU ÖZELLKLERNN NCELENMES 
 
 Çalkonlar (1,3-diaril-2-propen-1-on) flavanoid ailesine dahil olup, bir dizi 
biyolojik aktivititeye sahip olan bileikler olarak bilinirler. Çalkon türevleri anti-kanser, 
anti-bakteriyel, anti-inflamatuvar, anti-anjiogenik gibi geni bir spektrumda biyolojik 
aktivite gösterebilmektedir. Buna ek olarak çalkon boronik asit türevlerinin anti-kanser 
ve karbonhidratlara balanma kapasiteleri literatürde yeni çalıılan konulardır. Söz 
konusu çalımalarda çalkon boronik asit türevlerinin kanser hücrelerine karı seçici 
sitotoksik etkilerinin olduu rapor edilmidir. 
 Bu çalımada ise literatürde ilk olarak çift boronik asit türevlendirilmi çalkon 
türevleri ve 2-naftalin substituentli çalkon boronik asit türevlerinin sentezleri 
çalıılmıtır. Çift boronik asit çalkon türevlerini elde edebilmek için ticati olarak 
asetilfenil boronik asit türevleri ve formilfenil boronik asit türevleri bazik metanol 
içerisinde tepkimeye sokulmutur. Benzer koullarda 2-naftilaldehit ile asetilfenil 
boronik asitlerin kondensasyonundan tek boronik asit fonksiyonellendirilmi çalkonlar 
elde edilmitir. Sentezlenen çift boronik asit çalkon türevleri ve 2-naftil çalkon boronik 
asit türevlerinin aromataz inhibisyonu potansiyelleri, buna ek olarak meme kanseri 
hücre hattında (MCF-7) ve prostat kanseri (PC3) hücre hattlarında anti-proliferatif 
özellikleri test edilmitir. Ek olarak sentezlenen boronik asit türevlendirilmi çalkon 
bileiklerinin, D-fruktoz, D-glikoz ve D-galaktoz ile balanabilme testleri fizyolojik 
pH’da denenmidir. 
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CHAPTER 1  
 
INTRODUCTION 
 
 Cancer is the common name used to define more than two hundred diseases 
having similar characteristics. By the year of 2002, about 11 million cancer cases were 
reported in worldwide. Future estimations of cancer are incidence in worldwide 
predicted that there will be an increase and number of cases will be around 17 millions 
in 2020, and 27 millions in 2050 (Bray and Moller, 2005). These expectations force 
scientific communities to define or develop new cancer treatment methods. Treatment 
of a patient diagnosed with cancer can be depend on type of cancer, extent of 
metathesis, and sensitivity to treatment (Gabriel, 2007). 
 Cancers can be characterized by unregulated cell proliferation and migration in 
the body. It is well known fact that; multi-mutations of DNA in mitotic cells are the 
main reason for such unregulated cell proliferation. So it is clear that only the mutated 
mitotic cells are susceptible for cancer development. 
 In human body the tissues can be divided into four main groups; epithelial, 
connective, muscle and nervous tissues. But not all of these tissues have equal 
probability to develop cancer because of the differences in their ability to respond to 
cell loss. In some parts of the body, integrity of the tissues are controlled by 
proliferation of cells of cells to replace older, damaged or dead cells. In terms of cell 
replacement capability, tissues can also be derived into three parts; rapidly self 
renewing tissues (such as; skin, intestine and hematopoietic system), conditionally 
renewing tissues (such as; liver, breast, prostate and connective tissues), and non-
renewing tissues (such as; female germ line, and central nervous system). Among those 
renewable tissues have the types of cells which can develop cancer (Marshman et al., 
2005). 
 DNA in eukaryotic cells undergoes damage, repair, and resynthesis in a 
continuous manner. There are some checkpoints in healthy cells and any damage in the 
DNA can be repaired correctly. But this is not the case in cancer cells. In cancer cells 
this equilibrium is disturbed, and that allows multi-mutations in the DNA of cell and 
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causes immortal cell formation and invasion by these uncontrolled cells (Loeb, 2000). 
Thus cancer is not a localized disease but a disease that can spread other tissues via the 
lymphatic system and blood stream, creating secondary tumor regions (metastasis) 
(Gabriel, 2007). 
 Such mutations in DNA can be formed by genetic factors and environmental 
factors like smoking, diet, obesity, chemicals, and pollution etc. can result mutations in 
DNA therefore cancers. In addition, such chronic diseases are much more related with 
environmental factors compared to genetic factors. Studies have shown that; the 
connectivity between breast cancer and genetic factors was found to be only one in five 
in identical twins (Anand et al., 2008). 
 Since cancer is a fatal disease, there is still a need to develop new and effective 
anti-cancer agents to take carcinomas under control. To stop or reverse the development 
of cancer by using natural or synthetic substances is called cancer chemoprevention 
which was first described by Sporn (Sporn, 1976). 
 Chemopreventive agents play an important role to control cancer only if they 
target the genetically mutated cells which are the starting point of cancer. Second 
important point is chemopreventive agent should be highly effective at low doses. For 
that reason synthetic modifications of naturally occurring substances might improve the 
selectivity and potency of that naturally occurring chemopreventive compound. 
 Chalcones (Figure 1.1, 1) and its derivatives are a class of natural products 
belonging to flavanoid family, represent important biological activities, such as anti-
inflammatory, anti-oxidant, anti-cancer, and anti-bacterial. Chalcone derivatives are 
abundant in plants and relatively easy to produce unsubstituted derivatives in synthetic 
ways, and these properties make chalcones important candidates for chemoprevention. 
Up to date there are hundreds of chalcone derivatives either isolated from natural 
products or synthesized in laboratory conditions showing promising biological activities 
have been reported. Because it is not possible to review all of them in here, a few 
examples of those will be shown to clarify the importance of chalcones. 
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Figure 1.1. Simple chalcone structure. 
 
 Boronic acid compounds are promising candidates for prevention of cancer, 
based on their unique properties: (1) inter-convertibility between the trigonal and 
tetrahedral forms as carbonyl functional group does (2 and 3 Figure 1.2), (2) their strong 
binding ability with diol-functionalized compounds, (3) their Lewis acidity, and (4) 
beneficial unstability upon neutron bombardment. 
 
 
 
Figure 1.2. Inter-convertibility between the trigonal (2) and tetrahedral form (3) of 
phenyl boronic acid in water. 
 
 Although, pharmaceutical studies related with chalcones were done for a long 
time boronic acids are relatively new in pharmacy because of their unknown mode of 
actions. So, many researchers focus on to develop new boronic acid derivatives to fight 
with cancer. For this purpose in this study chalcone structure is chosen as a rigid carbon 
skeleton to arrange distances between two boronic acid moieties  
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1.1. Synthesis 
 
1.1.1. Synthesis of Chalcone Derivatives 
 
 Chalcones are readily synthesized by Claisen-Schmidt condensation reactions 
catalyzed by a strong base like NaOH or KOH. Claisen-Schmidt condensation reaction 
of substituted benzaldehydes and acetophenones favors (E)-isomer of chalcone 
derivatives in good yield. Lawrence et al. synthesized a small library of chalcone 
derivatives (Figure 1.3) starting from acetophenones and aldehydes having different 
functional groups in alkaline methanol solution, in reasonable yields (43-70%) 
(Lawrence et al., 2001). 
 
 
 
 
Figure 1.3. Synthesis of chalcone analogues 16-21 in basic solution. 
 
 Toda et al. go through a series of chalcone derivatives (Figure 1.4) that were 
formed up with NaOH in the absence of solvent. Efficient synthesis of chalcone 
analogues have been reported in high yields in a shorter time compared to the reactions 
performed in solvent (Toda et al., 1990). 
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Figure 1.4. Synthesis of chalcone analog 24 in the absence of solvent. 
 
 As an alternative, Eddair et al. reported an influential method for the synthesis of 
chalcone analogues (Figure 1.5) via Suzuki coupling reaction between benzoyl 
chlorides 26-31 and phenylvinyl boronic acid (25) in anhydrous toluene. In these 
reactions Mc Charty’s Suzuki Coupling conditions (Haddach and McCarthy, 1999) 
(solvent: anhydrous toluene; catalyst: tetrakis(triphenylphosphine)palladium(0); base: 
cesium carbonate) was used to produce chalcone analogues in high yields (68-93%) 
regardless of the types of substituents in phenyl rings (Eddair et al., 2003). 
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Figure 1.5. Synthesis of chalcone derivatives 1, 32-36 via Suzuki coupling reaction. 
 
 Chalcones can also be synthesized under acidic conditions. Either protic or 
Lewis acids can be used to perform aldol condensation reactions. AlCl3 (Calloway and 
Green, 1937), RuCl3 (Iranpoor and Kazemi, 1998) and TiCl4 (Mazza and Guaram, 
1980) are just few examples of Lewis acids, which can be used to catalyze the 
formation of chalcones .Narender and Reddy gave an example of acid catalyzed aldol 
condensation reaction (Figure 1.6) by using of borontrifluoride-etherate. Synthesis of 
chalcone analogues 41 and 42 were successfully accomplished at room temperature in 
reduced reaction times. This method also gave no side reactions and resulted in high 
yields (81-88%) to produce chalcones having electron withdrawing or donating groups 
on aryl rings (Narender and Reddy, 2007). 
 
 
 
 
Figure 1.6. Synthesis of chalcone derivatives 41 and 42 by acid catalyzed aldol 
condensation. 
 
1.1.2. Synthesis of Chalcone Boronic Acid Derivatives 
 
 Up to date, there are only few reported work dealing with the synthesis of 
boronic acid derivatized chalcones. In general base catalyzed Claisen-Schmidt reaction 
were performed in an alcoholic solution. One example for the synthesis of chalcone 
derivatives having boronic acid substituent 47-51 were reported by Kumar et al. simply 
from the Claisen-Schmidt condensation of corresponding acetophenone and 
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benzaldehyde derivatives in KOH-MeOH solution as shown in Figure 1.7 (Kumar et al., 
2003). 
 
 
 
 
Figure 1.7. Preparation of boronic acid chalcone derivatives 47-51 via Claisen-Schmidt 
condensation reaction. 
 
1.2. Biological Activities 
 
1.2.1. Biological Activities of Chalcones 
 
 Natural and synthetic chalcone derivatives have a broad range of biological 
applications, and only few of the biological activities of chalcones will be discussed 
under this title: anti-inflammatory activity, antibacterial activity, antioxidant activity 
and anticancer activity with examples.  
 
1.2.1.1. Anti-inflammatory Activity 
 
 Chronic inflammation accepted as a risk factor that can lead cancer, since the 
relationship between tumor and inflammation has been first pioneered by Rudolf 
Virchow (Smith and Missailidis, 2004). Nitric oxide is an important component of 
inflammatory responses. Large quantities of free radical nitric oxide (NO) production 
by activated macrophages in human body (Molina et al., 2001), may lead toxicities and 
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tumor development (Kaur et al., 1994). Rojas et al. reported two chalcone derivatives 52 
and 53 (Figure 1.8) that were found to be effective inhibitors of nitrite production 
having IC50 values 0.28 µM and 0.03 µM respectively (Rojas et al., 2002). 
 
 
 
Figure 1.8. Compounds 52 and 53 having anti-inflammatory property. 
 
1.2.1.2. Anti-bacterial Activity 
 
 Nielsen et al. reported a series of chalcone derivatives (Figure 1.9) showing anti-
bacterial effect against the gram-positive bacterium S. aureus ATCC 29213. Chalcone 
derivatives 54 and 55 are highly effective anti-bacterial agents in vitro with minimal 
inhibition concentrations (MIC) of 2 µM and not shown cytotoxisity (measured by MTT 
reduction) even at 100 µM concentrations (Nielsen et al., 2004). 
 
 
 
Figure 1.9. Structures of chalcone derivatives 54 and 55 reported having anti-bacterial 
properties. 
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1.2.1.3. Antioxidant Activity 
 
 Forms of reactive oxygen species, such as superoxide anion (O2-), hydroxy 
radical (OH-) and hydrogen peroxide (H2O2) can produce oxidative stress and give 
damage to biological macromolecules to lead into serious diseases, even cancer. 
Antioxidant molecules can react with these highly reactive oxygen species and prevent 
the formation of any possible damage on biological macromolecules. Flavanoid family 
of compounds are well known for their anti-oxidant properties. As an example Bandgar 
et al., reported some simple methoxlated chalcone derivatives as potential anti-oxidation 
agents. Chalcone derivative 56 (Figure 1.10) has a moderate antioxidant efficiency and 
bioavailability. Compound 56 have also shown to be non-toxic on healthy cells. 
(Bandgar et al., 2009). 
 
 
 
Figure 1.10. Structure of chalcone derivative 56 having anti-oxidant property. 
 
1.2.1.4. Anti-cancer Activity 
 
 A naturally occurring chalcone derivative licochalcone A (57 Figure 1.11), is a 
major phenolic constituent of Glycyrrhiza inflata that shows significant anti-tumor 
activity in human cancer cell lines (Kim et al., 2010).  
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Figure 1.11. Licochalcone A. 
 
 Cell cytotoxicity assays are used as a primary screening method for anti-cancer 
drug development. MTT assay is one of the most common method to determine 
cytotoxic activity of anti-cancer agent. Lawrence et al. announced highly cytotoxic 
chalcone analogues 16 and 58 over K 562 (human leukemia) cancer cell line. 
Compounds 16 and 58 (Figure 1.12) cause to inhibit K 562 cells proliferation 50% at 30 
nM and 40 nM respectively determined by MTT assay. (Lawrence et al., 2001) 
 
 
 
Figure 1.12. Chalcone derivatives 18 and 58 possessing anti-cancer activity. 
 
1.2.3. Biological Activities of Boronic Acid Functionalized Molecules 
 
 Boronic acid functionalized compounds are important biologically active agents 
that have been used for various biological applications such as; enzyme inhibition, 
building sensors and lectin mimics (boronolectins), in transmembrane transporters, in 
bioconjugations, protein immobilization and boron neutron capture therapy (BNTC) 
agents (Yang et al., 2005). 
 
11 
 
1.2.3.1. Boronic Acid Derivatives as Enzyme Inhibitors 
 
 Thrombin is a serine protease protein involved in blood coagulation cascade, is a 
target for the development of thrombin inhibitors. Inhibition of thrombin decreases the 
risk of obstruction of blood vessels by coagulation. DUP 714 (59) is a well known 
boronic acid derivatized peptide that inhibits thrombin effectively (Ki = 0.04 nM). In 
vivo studies of DUP 714 in laboratory animals showed serious side effects. Fevig et al. 
reported another boronic acid derivatized peptide 60 (Figure 1.13) that selectively 
inhibits thrombin (Ki = 0.06 nM). Compared to DUP 714, compound 60 has decreased 
the side effects in vivo studies (Fevig et al., 1998). 
 
 
 
Figure 1.13. Structure of DUP 714 (59) and compound 60 that inhibit thrombin activity. 
 
1.2.3.2. Boronolectins 
 
 Carbohydrates are involved in the metabolic pathways of living organisms; 
therefore, modification of cell surface carbohydrates are associated with the 
development and progression of many types of diseases including cancer. Thus, it is 
crucial to develop carbohydrate sensors under physiologic conditions for early detection 
of cancer. Recognition of carbohydrates by these sensors mimics the action of lectins so 
these sensors are called as artificial lectins. Because of these lectin mimics contain 
boronic acid moieties they are called boronolectins (Yang et al., 2005). Yang et al. 
reported a boronolectin compound 61 (Figure 1.14) that differentiate sialyl Lewis X 
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expressing cells from non-sLex expressing cells by high fluorescence intensity change 
(Yang et al., 2002). 
 
 
 
 
Figure 1.14. A boronolectin compound 61 reported by Yang group. 
 
1.2.3.3. BNCT Agents 
 
 The unique property of 10B isotope bombarded by low energy neutrons can be 
decomposed into 7Li ions and 4He nuclei thus producing gamma particiles without 
producing other types of ionizing radiation. This unique property of boron makes its 
derivatives an indispensable candidate for boron neutron capture theory (BNTC) (Yang 
et al., 2003).  
 Nemoto et al. reported a water soluble boronic acid derivative, which is uptake 
by cancer cells rather than healthy cells. p-Boronophenylalanine (BPA) derivative 62 
(Figure 1.15) have been tested for its ability to be a BNCT agent. After 18 days of in 
vivo test, the tumor volume was decreased to approximately 18% by using [10B]BPA-
(OH)2 (62) (Nemoto et al., 1995). 
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Figure 1.15. An aryl boronic acid derivative 62 as a BNTC agent. 
 
1.2.4. Biological Activities of Boronic Acid Chalcone Derivatives 
 
 Because of the essential biological properties of chalcones and boronic acids 
there are just a few literature works for boronic acid derivatized chalcones showing anti-
tumor, anti-cancer and anti-angiogenesis activities. Some of the examples of those 
literature works are summarized under this title. 
 
1.2.4.1. Anti-cancer Activity 
 
 As discussed earlier, chalcone derivatives are potent anti-cancer drug candidates 
that have promising therapeutic efficacy to cope with cancer disease. Kumar et al. 
hypothesized that chalcone boronic acid analogues were selectively inhibit growth of 
breast cancer cells, with minimal effect on healthy cells. For this purpose they 
synthesized new boronic acid substituted chalcone analogues and compared their 
cytotoxic activities with those of chalcone analogues which are not substituted with 
boronic acid.  
 Bortezomib (63 Figure 1.16) is a boronic acid functionalized peptide derivative 
which is a perfect example for the use of boronic acid compounds on cancer treatment. 
It was granted by the US Food and Drug Administration in early 2003, as a single agent 
for the treatment of multiple myeloma, a bone marrow cancer that affects two to three 
people per 100.000 (Paramore and Frantz, 2003). 
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Figure 1.16. Structure of Bortezomib. 
 
 Boronic acid substituted chalcone 64 inhibits growth of MDA-MB-231 (Human 
breast cancer estrogen receptor negative), MCF-10A (Healthy breast epithelial) cell 
lines with IC50 value of 8.8 µM and 75 µM. Compound 65 is equally toxic to MDA-
MB-231 and MCF-10A cell lines with IC50 value of 44 µM (Kumar et al., 2003). 
Compound 66 having a similar structure compared to compound 65 except of boronic 
acid moiety and it inhibits proliferation of MDA-MB-231 cancer cell lines with 50% at 
15.1 µM concentration (Modzelewska et al., 2006). 
 
 
 
 
Figure 1.17. Boronic acid substituted chalcone derivatives 64, 65, and 66 as anti-tumor 
agents. 
 
 A study by Modzelewska et al. reported that chalcone derivatives having two 
boronic acid moieties (Figure 1.18) exhibited higher in vitro cytotoxic activity 
compared to single boronic acid substituted chalcones. To show that, single boronic 
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acid substituted chalcone derivatives and bis-chalcone boronic acid derivatives were 
prepared and tested for their possible anticancer activities on human breast cancer cell 
line (MDA-MB-231). Compound 67 is found cytotoxic on MDA-MB-231 cancer cell 
lines with IC50 values of 350 nM (Modzelewska et al., 2006). 
 
 
 
Figure 1.18. Bis-chalcone boronic acid derivative 67 that show high cytotoxic activity 
against cancer cells. 
 
1.2.4.3. Anti-angiogenesis Activity 
 
 Angiogenesis, the growth of the new blood vessels to supply food and oxygen, is 
necessary for cancerous tumors to keep growing and spreading (NCI, 2011). Kong et al. 
reported that boronic acid chalcone derivative 68, which inhibits the growth of new 
blood vessels in HUVEC (human umbilical vein endothelial cells) in 1 µM 
concentration. Also in aortic ring assay compound 68 shows inhibition of angiogenesis 
in 5 µM concentration (Kong et al., 2010). 
 
 
Figure 1.19. Structure of compound 68 showing anti-angiogenesis activity. 
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1.3. Carbohydrate Sensors  
 
 Boronic acids are the most commonly used functional group for the construction 
of sensors for carbohydrates because of their strong interactions with 1,2-diols or 1,3-
diols to form five or six membred cyclic esters,. These lectin mimicking compounds are 
called boronolectins because they all contain boronic acid functionality (Jin et al., 
2010). 
 There are several equilibriums, which should be noticed during the binding of a 
boronic acid to a diol in water (Figure 1.20). These include: Ktrig to describe the 
equilibrium between the two boronic acid species 2 and 69; Ktet to describe the 
equilibrium between the un-complexed 3 and 70; Keq to describe the overall binding 
process between 2, 3 and the complexed species 69, 70 (Figure 1.21) (Yan et. al., 2005). 
 
 
 
Figure 1.20. Binding equilibrium between phenyl boronic acid and diol in water. 
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Figure 1.21. Overall binding constant Keq. 
 
  In literature there are different sensitive methods to determine the binding 
constant of boronic acids with diols. Early approaches to determine the binding were pH 
depression and 11B-NMR method. Long experiment times and requirement for large 
amount of sample are the disadvantages of these methods. Spectroscopic methods are 
favorable in recent studies, which are fast, sensitive, easy to use and require small 
quantity of sample. In such methods to determine binding between a boronic acid and a 
diol, the binding process has to change the spectroscopic properties of the boronic acid 
sensor. There are many boronic acid compounds that show significant fluorescent 
property changes upon diol binding. These boronic acid compounds are called boronic 
acid fluorescent reporter compounds (Yan et al., 2005). According to their fluorescent 
properties, ICT (Internal Charge Transfer) sensors and PET (Photoinduced Electron 
Transfer) sensors occupies a respectable place in literature (James,2005). 
 
1.4.1. Internal Charge Transfer (ICT) Sensors 
 
 DiCesare et al. investigated new boronic acid chalcone derivatives (71, 72: 
figure 1.22) for the development of fluorescent probes based on the internal charge 
transfer (ICT) mechanism. The equilibrium between their neutral and anionic form 
through the binding process to a diol, altered the electron withdrawing property of the 
boron, thus cause a large change in fluorescence intensities and wavelength shifts. 
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Compound 71 and 72 produced large fluorescence changes in phosphate buffer (2:1 
water/MeOH (v/v) at pH 7.0) in the presence of varying amount of carbohydrates. Kd 
values of 71 and 72 for tested carbohydrates are given in Table 1.1 (DiCesare and 
Lakowicz, 2002). 
 
 
 
Figure 1.22. Structures of boronic acid chalcones 71 and 72, used as Internal Charge 
Transfer (ICT) saccharide sensors. 
 
Table 1.1. Reported binding constants of 71and 72.with D-fructose, D-galactose and D-
glucose. 
 
Compound 
Carbohydrate 
71 72 
KD 
D-Fructose 2.1 2.5 
D-Galactose 14 16 
D-Glucose 34 30 
 
 Since internal charge transfer (ICT) is an important mechanism for fluorescent 
signaling, Arimori et al. prepared an ICT fluorescent sensor 73 (Figure 1.23) for 
saccharides. Compound 73 shows significant fluorescence intensity change and a shift 
in wavelength with increasing saccharide concentration in 0.1 M potassium dihydrogen 
phosphate buffer (52.1 wt% MeOH/Water at pH 8.21). In the presence of saccharides 
the shift in fluorescent wavelength is caused by the transformation of the single 
unbound formation of compound 74 (Figure 1.24(a)) to a single saccharide bound 
formation 75 (Figure 1.23(b)). The appearing binding constant Kapp for saccharide 
complexes of fluorescence sensor 73 are shown in Table 1.2 (Arimori et al., 2001). 
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Figure 1.23. Compound 73 as an ICT saccharide sensor. 
 
 
 
Figure 1.24. The unbound formation 74 and a single saccharide bound formation 75 
forms of compound 73. 
 
Table 1.2. Reported binding constant Kapp values of compound 73 with D-fructose, D-
galactose and D-glucose. 
 
Compound 
Carbohydrate 
73 
Kapp (M-1) 
D-Fructose 106 ± 7 
D-Galactose 27 ± 4 
D-Glucose 18 ± 6 
 
1.4.2. Photoinduced Electron Transfer (PET) Sensors 
 
 Photoinduced electron transfer (PET) has been widely used as the preferred tool 
in fluorescent sensor design for atomic and molecular species. PET sensors generally 
consist of a fluorophore and a receptor linked by a spacer. Changes in 
oxidation/reduction potential of the receptor upon guest binding can affect the PET 
process, resulting changes in fluorescence (James, 2005). 
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 de Silva et al. figured out a single simple picture (Figure 1.25) summarizes the 
design of fluorescent PET sensors. The fluorophore, spacer and receptor format is a 
combination of three components. Electron delocalization from un-bound receptor to 
excited fluorophore forms the ‘off’ state of PET sensors (Figure 1.26 (a)). Blocked 
electron delocalization from carbohydrate bound receptor forms the ‘on’ state of PET 
sensors emitting an energy in the form of fluorescence light (Figure 1.26 (b)) (de Silva 
et al., 2009). 
 
 
 
Figure 1.25. The fluorophore-spacer-receptor combination of fluorescent PET sensors. 
(Source: de Silva et al., 2009) 
 
 
 
Figure 1.26. PET sensor mechanism. 
(Source: de Silva et al., 2009) 
 
 James et al. improved selectivity of fluorescent PET sensor 76 by introducing a 
second boronic acid functionality as it’s shown by molecule 77. Due to spacing of the 
boronic acid moieties the diboronic acid compound 77 was selective for D-glucose over 
other saccharides including D-fructose in phosphate buffer (33.3 wt% methanol-water at 
pH 7.77). Binding constants (Kapp) are shown in Table 1.3 (James et al., 1995). 
 
21 
 
 
Figure 1.27. Structure of compound 76 and selective PET sensor 77 for glucose reported 
by James and coworkers. 
 
Table 1.3. Reported Kapp (binding constants) values of PET sensors 76 and 77 with D-
fructose and D-glucose. 
 
Compound 
Sugar 
76 77 
Kapp (M-1) 
D-Fructose 1000 320 
D-Glucose 60 4000 
 
 Diboronic acid functionalized compound 78 (Figure 1.28) with a small spacer 
between the boronic acid groups was synthesized by James et al. and shown to be 
selective for D-sorbitrol in phosphate buffer (300:1 v/v water/methanol at pH 8). 
Binding constants (Kapp) of compound 78 are given in Table 1.4 (James et al., 1997). 
 
 
Figure 1.28. Selective D-sorbitrol sensor compound 78. 
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Table 1.4. Binding constants for compound 78 with D-fructose and D-sorbitrol. 
 
Compound 
Carbohydrate 
78 
Kapp (M-1) 
D-Fructose 330 
D-Sorbitrol 350 
 
1.4. Aromatase Inhibitors 
 
 Aromatase is an enzyme that catalyses the estrogen production. Since estrogen is 
an essential hormone and high level of estrogen was involved in the development and 
growth of breast tumors, inhibition of aromatase is vital for the treatment of cancer. 
Thus, there are several aromatase inhibitors in literature. In general aromatase inhibitors 
are classified into two main parts: steroidal inhibitors (form a stable bond with the 
aromatase enzyme complex) and non-steroidal inhibitors (inhibit the enzyme by 
reversible competition) (Brueggemeier et al., 2005). 
 
1.4.1. Steroidal Aromatase Inhibitors 
 
1.4.1.1. Competitive Aromatase Inhibitors 
 
 These type of enzyme inhibitors compete with the substrate to bind itself to 
enzyme by intermolecular attraction forces (noncovalent binding) to reduce the 
formation of estrogen. Brueggemeier et al. reported a potent steroidal aromatase 
inhibitor 79 (Figure 1.29). The reported inhibition constant for the reversible binding 
(Ki) of 79 was 18 nM in human placental microsomes (Brueggemeier et al., 1987). In 
another study Brueggemeier et al. studied aromatase inhibition property of compound 
79 in MCF-7 cell culture in a dose-dependent fashion, with an ED50 (effective dose) of 
compound 79 was reported as 25.07 nM (Brueggemeier et al., 1978). 
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Figure 1.29. Structure of steroidal competitive aromatase inhibitor 79. 
 
1.4.1.1. Enzyme Activated Irreversible Aromatase Inhibitors 
 
 Enzyme activated irreversible inhibitors act as a substrate that binds to the 
enzyme, so inactivation of the enzyme occur. Because of these inhibitors mimic 
substrate perfectly without causing any other interactions in biological pathways they 
are unique candidates for enzyme inhibition. Inactivation of the enzyme is described by 
a half time of inactivation at infinite inhibitor concentration (t1/2) and the rate of 
inactivation (Kinact) (Brueggemeier et al., 2005). 
 Brodie et al. indicated a competitive aromatase inhibitor 80, produces enzyme 
mediated-inactivation. In enzyme inhibition assays, compound 80 (Figure 1.30) 
exhibited a half time of inactivation at infinite inhibitor concentration (t1/2) of 2.57 min 
and rate of inactivation (Kinact) of 4.50 x 10-4 sec-1 (Brodie et al., 1981). 
 
 
Figure 1.30. Structure of steroidal enzyme activated irreversible aromatase inhibitor, 80. 
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1.4.2. Non-steroidal Aromatase Inhibitors 
 
1.4.2.1. Triazole Based Aromatase Inhibitors 
 
 Triazole rings are used as potentially non-steroidal inhibitors of aromatase 
enzyme. Letrozole (81 Figure 1.31) is a triazole derivative that causes 50% aromatase 
enzyme inhibition effectively at 11.5 nM in human placental microsomes (Bhatnagar et 
al., 1990). 
 
 
Figure 1.31. Structure of triazole based aromatase inhibitor, 81. 
 
1.4.2.2. Flavanoid Derivatives as Aromatase Inhibitors 
 
 The observation of the lower breast cancer ratios of the regions that have 
abundant nutrients like soy and rye flour lead the hypothesis that the flavonoids, that are 
abundant in these nutrients, were responsible for lower breast cancer incidences in 
women. Flavonoids are found to be inhibitory agents for aromatase enzyme thus 
lowering estrogen levels and decrease the risk factor for the development of cancer. 
However, biological active flavonoids may be involved in many therapeutic pathways 
and thus can limit their uses (Brueggemeier et al., 2005). 
 Pouget et al. showed synthesis and human placental aromatase inhibitory action 
of novel flavanones (82 and 83 Figure 1.32). Compound 82, and 83 inhibit human 
placental aromatase 50% at 2.5 µM and 3.5 µM concentrations respectively (Pouget et 
al, 2002). 
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Figure 1.32. Structures of flavanone derivatives 82, and 83 inhibiting aromatase 
enzyme. 
 
 Le Bail et al. demonstrated for the first time that chalcone derivatives are potent 
inhibitors of aromatase. They noted that flavones and flavanones generally inhibit 
aromatase activity more than chalcone derivatives do except with naringenin chalcone 
(84) and eriodictyol chalcone (85) (Figure 1.33). Reported IC50 values of those are 2.6 
µM and 2.8 µM respectively (Le Bail et al., 2001). 
 
 
 
Figure 1.33. Structures of chalcone derivatives 84, and 85 inhibiting aromatase enzyme. 
 
 Another study of aromatase inhibition activity by chalcone and flavanone 
derivatives was reported by Maiti and coworkers. Maiti group showed that flavanones 
are much more efficient aromatase inhibitors. Chalcone 86 and flavanone 87 have the 
same functional groups on their aromatic regions. Chalcone 86 and flavanone 87 inhibit 
aromatase enzyme by 50% at 82.94 µM and 4.08 µM concentrations respectively (Maiti 
et al., 2007). 
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Figure 1.34. Structures of chalcone and flavanone derivatives 86 and 87 exhibiting 
aromatase inhibition. 
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CHAPTER 2 
 
RESULTS AND DISCUSSIONS 
 
2.1. Synthesis of Boronic Acid Chalcone Derivatives 
 
 As discussed in the introduction part, chalcone and boronic acid derivatives are 
promising drug candidates for chemoprevention of cancer. A recent study also shows 
that, chalcone derivatives having boronic acid either on its pehenolic A or B ring are 
effective anti-cancer drug candidates. But to the best of our knowledge, diboronic acid 
chalcone derivatives have never been synthesized or tested for their biological activities 
in literature. 
 Because modifications on the cell surface carbohydrates play important role for 
cancer development, it would be a good choice to synthesize molecules which are 
targeting or binding carbohydrates. Therefore, in this work it is aimed to synthesize 
chalcone derivatives substituted by two boronic acids by Claisen-Schmidt reaction 
starting from corresponding acetylphenyl or formylphenyl boronic acids (Figure 2.1). 
 Additionally, fluorescent properties of chalcones are well known in literature. 
Replacement of one of the phenyl ring in chalcone with naphthyl may help to increase 
fluorescence intensity of from the chalcone and presence of a boronic acid on the other 
phenyl group of chalcone may convert the chalcone into a carbohydrate sensor. For that 
reason, it is also aimed to prepare boronic acid naphthyl chalcones substituted with 
starting from corresponding 2-naphthaldehyde and acetyl phenyl boronic acids (Figure 
2.1). 
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Figure 2.1. Structures of proposed mono and diboronic acid substituted chalcone 
derivatives 93-100. 
 
2.1.1. Synthesis of Diboronic Acid Chalcone Derivatives 
 
 To yield 2,4’-diboronic acid chalcone derivative 93 different  reaction conditions 
were tried. However, all of the reactions carried out between 2-formylphenyl boronic 
acid (88) and 4-acetylphenyl boronic acid (46) gave either no reaction or inseperable 
mixtures of products. In these attempts, both acidic (BF3.OEt2) and basic (KOH, NaOH, 
KOtBu) conditions were used to catalyze the reaction in alcohol or dioxane (Table 2.1). 
Reactions definitely do not yield any product formation at lower temperatures or shorter 
reaction times under reflux. Purification of boronic acid derivatives in silica gel column 
is a challenging subject and most of the time 100% recovery is impossible (Hall, 2005). 
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Table 2.1. Reaction conditions performed for the preparation of compound 93. 
 
 
Entry 
Conditions 
Yield 
Base/Acid Solvent Temp. Time 
1 NaOH - RT 20 min. No Rxn 
2 NaOH EtOH 70 ºC 6 h No Rxn 
3 NaOH EtOH 70 ºC 48 h Inseparable mixture 
4 KOtBu EtOH reflux 12 h Inseparable mixture 
5 NaOH EtOH reflux 24 h Inseparable mixture 
6 KOtBu MeOH reflux 12 h No Rxn 
7 KOtBu MeOH reflux 24 h Inseparable mixture 
8 NaOH MeOH reflux 24 h No Rnn 
9 NaOH MeOH reflux 24 h Inseparable mixture 
10 KOH MeOH reflü 48 h Inseparable mixture 
11 NaOH DMSO Reflux 24 h Inseparable mixture 
12 NaOH H2O RT - No rxn 
13 BF3.OEt2 Dioxane RT 6 h No rxn 
 
 Crude products of the reactions was also analyzed by 1H-NMR to identify the 
formation of 
,-unsaturated carbonyl functionality. Although there was not any sign 
for the formation of 
,-unsaturated carbonyls, crude products were applied to flash 
column chromatography to identify the resulted side products. 
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 Only one of the crude product, reduced form of 2-formylphenyl boronic acid 
could be identified, which implies the formation of Cannizzaro reaction. Interestingly 2-
formylphenyl boronic acid or 4-acetylphenyl boronic acid alone did not give any new 
product formation under the same reaction conditions. 
 Although, separation of boronic acid derivatives in silica gel column possible, 
separation of boronate esters are easier as regarded in literature (Yan et al., 2005). For 
that reason it might be a good choice to convert the boronic acids to their ethylene 
glycol esters (Figure 2.2) and then to carry out the Claisen-Schmidt reaction (Figure 
2.4). Ethylene glycol esterification of boronic acids were performed at room 
temperature in the presence of anhydrous MgSO4 successfully to produce 101 and 102. 
But purification of the products from unreacted ethylene glycol was not possible in our 
hands. Afterwards crude products of boronate diethyl glycol esters 101 and 102 were 
reacted under basic condition to produce the corresponding protected diboronic acid 
chalcone derivative but reaction gave again an inseparable mixture (Figure 2.3). 
 
 
 
Figure 2.2. Protection of boronic acid functionality with ethylene glycol. 
 
 Because all of the attempts toward the preparation of 2,4’-diboronic acid 
derivatized chalcone was failed, the rest of the study was carried out by 3-formyl and 4-
formyl phenyl boronic acids. Synthesis of 2,3’-diboronic acid derivatized chalcone (94) 
was not attempted due to the Cannizaro reaction of 2-formylphenyl boronic acid. 
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Figure 2.3. Reaction conditions performed for preparation of compound 103. 
 
 For the synthesis of 3,3’-diboronic acid substituted chalcone derivative 
corresponding boronic acid functionalized benzaldehyde 89 and acetophenone 92 was 
stirred under acidic or basic conditions (Table 2.2). Synthesis was successfully 
completed in MeOH in the presence of excess sodium hydroxide under reflux with 84% 
yield. In other attempts, low concentrations of sodium hydroxide or presence of amine 
base did not give any successful product formation. Additionally acid catalyzed reaction 
(BF3.OEt2) gave 63% yield for the target chalcone product formation. 
 
Table 2.2. Reaction conditions performed for the preparation of compound 95. 
 
 
Entry 
Conditions 
Yield 
Base Solvent Temp. Time 
1 NaOH MeOH Reflux 24 h No Rxn 
2 BF3.OEt2 Dioxane RT 8 h 63% 
3 NEt3 DMSO RT  60 ºC 48 h No Rxn 
4 
NaOH / Mol. 
Sieve 
EtOH RT 24 h No Rxn 
5 NaOH (excess) MeOH reflux 4 h 84% 
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 The all reaction attempts between 4-formylphenyl boronic acid and 4-
acetylphenyl boronic acid to yield 4,4’-diboronic acid chalcone derivative was 
performed in alcoholic alkaline solution. In the presence of excess amount of base, 
reaction proceeded smoothly but the separation of the boronic acid derivatives was a 
little bit problematic. The difficulty was mainly caused by the different behavior of 
boronic acid derivatives in TLC and flash column chromatography. By the usage of 
acetic acid in the eluent system of column chromatography, the tailing effect of boronic 
acid compounds was obstructed. For entries 3, 4 and 5 during the purification of product 
by flash column chromatography, acetic acid was used at 0.1%, 0.5% and 1% 
concentrations respectively. The purification of the product was best performed by the 
use of 1% acetic acid in eluent system in flash chromatography to give 94% yield 
(Table 2.3). 
 
Table 2.3. Reaction conditions performed for the preparation of compound 96. 
 
 
Entry 
Conditions 
Yield 
Base Solvent Temp. Time 
1 NaOH MeOH Reflux 24 h No rxn 
2 NaOH MeOH Reflux 24 h 
Inseparable 
mixture 
3 NaOH (excess) MeOH Reflux 24 h 45% 
4 NaOH (excess) MeOH Reflux 24 h 74% 
5 NaOH (excess) MeOH Reflux 24 h 94% 
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 Last two of the diboronic acid chalcone derivatives 3,4’- (97) and 4,3’-diboronic 
acid chalcone (98) were prepared under the same reaction conditions, performed to 
synthesize previous diboronic acid acid chalcones (Figure 2.4, Figure 2.5). But 
purification of these two diboronic acid chalcone derivatives was a little bit problematic 
compared to that of compound 95 and 96. Although 1% acetic acid was used in the 
eluent system of flash column, totally purification of 97 and 98 from the starting 
materials was not possible. Only 44% and 34% of the products 97 and 98 were fully 
separated from reaction mixtures. 
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Figure 2.4. Reaction conditions performed for preparation of compound 97. 
 
 
 
Figure 2.5. Reaction conditions performed for preparation of compound 98. 
 
2.1.2. Synthesis of 2-Naphthyl Chalcone Boronic Acid Derivatives 
 
 Claisen-Schmidt condensation reaction between 2-naphthaldehyde and 
acetylphenyl boronic acid derivatives was performed under basic conditions (Table 2.4). 
Reaction of 2-naphthaldehyde with 4-acetylphenyl boronic acid gave product formation 
in all attempts but the purification of those are quite challenging because of the close Rf 
values of products with the starting material (4-acetylphenyl boronic acid 46). 
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Table 2.4. Reaction conditions performed for preparation of compound 99. 
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Entry 
Conditions 
Yield 
Base Solvent Temp. Time 
1 KOtBu tBuOH 70 ºC 24 h Inseparable mixture 
2 NaOH MeOH Reflux 24 h Inseparable mixture 
3 KOH H2O RT - Inseparable mixture 
4 KOH MeOH/H2O Reflux 48 h Inseparable mixture 
5 NaOH MeOH/H2O Reflux 24 h 44% 
 
 To overcome this problem two different approaches was tried. In the first case 
the mixture obtained from column chromatography was subjected to crystallization. 
This approach gave 44% of product in pure form. In the second case, boronic acid 
derivatized chalcone (99) and 4-acetylphenyl boronic acid mixture was converted into 
its pinacol ester to create a Rf difference, but ester forms of those boronic acids have 
also similar Rf values, so column chromatography was failed (Figure 2.6). 
 
 
 
Figure 2.6. Esterification of boronic acid moieties on 2-naphthyl chalcone boronic acid 
with pinacol. 
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 As an alternative to the second approach, esterification of 4-acetyl phenyl 
boronic acid (46) with pinacol was performed before the Claisen-Schmidt reaction. 
Although esterification reaction was proceeded smoothly, again formation of 
inseparable mixture from Claisen-Schmidt reaction observed. (Figure 2.7). 
 
 
 
Figure 2.7. Esterification of 4-acetylphenyl boronic acid (46) with pinacol and reaction 
of pinaco ester form of acetophenone (105) and 2-naphthaldehyde (91). 
 
 At last, 2-naphthaldehyde was reacted with 3-acetylpheny boronic acid to form 
chalcone 100 under alcoholic alkaline solution and product was purified by the same 
procedure explained for chalcone 99 (Figure 2.8). 
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Figure 2.8. Reaction conditions performed for preparation of compound 100. 
 
2.2. Carbohydrate Binding Tests for Boronic Acid Chalcone 
Derivatives 
 
 Synthesized mono and diboronic acid chalcone derivatives were tested for their 
binding capability with D-fructose, D-galactose and D-glucose (Figure 2.9). Fluorescent 
studies of diboronic acid functionalized chalcones were performed in 0.1 M phosphate 
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buffer at pH 7.4 containing 1% DMSO. All of the diboronic acid chalcones are excited 
between 320-325 nm wavelengths and gave no remarkable fluorescence emissions. 
Therefore, diboronic acid chalcones may not be used as carbohydrate sensors at 
physiological pH. 
 
 
 
Figure 2.9. Structures of D-fructose, D-galactose and D-glucose. 
 
 Although fluorescence properties of diboronic acid chalcone derivatives did not 
changed in the presence of carbohydrates at physiological pH, it does not mean the lack 
of interactions between carbohydrates and diboronic acid chalcones. Because, 
requirement for fluorescence intensity change is the complexation of both boronic acids 
in tetrahedral form with carbohydrates at the same time (DBAC 5, figure 2.10). Binding 
of an only one boronic acid moiety with carbohydrate maybe lacks of fluorophore 
which should cause fluorescence emission. 
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Figure 2.10. Possible diboronic acid chalcone (DBAC) forms in 0.1 M phosphate buffer 
at pH 7.4 containing 1% DMSO. 
 
 On the other hand, 2-naphthyl chalcone boronic acids have stronger fluorescence 
responses itself. Both compounds were excited at 340 nm and a fluorescence emission 
maximum were observed at 523 nm. At physiological pH, fluorescence intensity of 
compound 99 increases with increasing concentrations of carbohydrates. In the presence 
of 100 mM D-fructose compound 99 gave a maximum which is 73 fold stronger 
compared to chalcone itself. Similarly 15 fold and 5 fold increases are observed in the 
fluorescence intensity with D-galactose and D-glucose respectively. Changes in the 
fluorescence spectrum of compound 99 in varying concentrations of D-fructose is 
shown in figure 2.11. Relative fluorescence intensity changes of compound 99 with 
different concentrations of D-fructose, D-galactose and D-glucose was summarized in 
figure 2.12. The appearing binding constants (Kapp) are calculated according to Benesi-
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Hildebrand method, assuming 1:1 binding was occurred. A sample Kapp calculation for 
compound 99 upon binding to fructose was shown in figure 2.13. 
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Figure 2.11. Fluorescence intensity change of compound 99 in the presence of varying 
concentrations of D-fructose. 
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Figure 2.12. The plot for normalized fluorescence intensity to log[saccharide] in the 
presence of D-fructose , D-glactose , D-glucose  for compound 99 
(3.30 x 10-5 M) in 0.1 M phosphate buffer at pH 7.4 	ex = 340 nm and 	em 
= 523 nm. 
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If If0 If-If0 
[D-Fructose] 
(M) 1/saccharide 1/  If slope intercept 
Kapp (M-
1) 
14.14034 
11.53 
2.61 0.0001 10000 0.383162 
3.81E-
05 
0.0029 76,1 
31.77098 20.24 0.001 1000 0.049406 
63.28095 51.75 0.0025 400 0.019323 
110.1764 98.65 0.005 200 0.010137 
186.2089 174.68 0.01 100 0.005725 
316.7682 305.24 0.02 50 0.003276 
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Equation y = 3.81E-05x + 0.0029 
If = Fluorescence intensity of complexed species. 
If0 = Fluorescence intensity of compound 99 itself. 
D-Fructose (M) = Concentrations of fructose. 
Slope = Slope of the plot calculated. 
Intercept = Intercept of the plot calculated. 
Kapp = Intercept/Slope 
 
Figure 2.13. Kapp calculation for compound 99 upon binding to fructose. 
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 Appearing binding constants of compound 99 with D-fructose, D-galactose and 
D-glucose are calculated as 76.1 M-1 and 23 M-1 respectively (Table 2.5). 
 
Table 2.5. Calculated Kapp binding constants and r2 values for various saccharides of 
compound 99. 
 
Compound 
 
Carbohydrate 
101 
Kapp (M-1) r2 
D-Fructose 76.1 0.99 
D-Galactose 23 0.98 
D-Glucose NA NA 
 
 Similarly fluorescence intensity of compound 100 increases with the 
concentrations of carbohydrates present in the buffer solution. Fluorescence spectra of 
compound 100 gave a maximum at 524 nm when it is excited at 340 nm. In the 
presence of 100 mM D-fructose compound 100 gave an emission intensity maximum 
which is 33 fold stronger than chalcone 100 in the absence of D-fructose. Similarly 8 
fold and 4 fold fluorescence intensity changes was observed for D-galactose and D-
glucose correspondingly. Changes in the fluorescence spectrum of compound 100 in 
varying concentrations of D-fructose is shown in figure 2.14. Relative fluorescence 
intensity changes of compound 100 in different concentrations of D-fructose, D-
galactose and D-glucose are shown in figure 2.15. Calculated appearing binding 
constants of compound 100 upon binding to D-fructose, D-galactose and D-glucose are 
27.5 M-1, 0.7 M-1 and 1.3 M-1 respectively (Table 2.6). 
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Figure 2.14. Fluorescence intensity change of compound 100 in the presence 0 to 100 
mM of D-fructose 100 (3 x 10-5 M) in 0.1 M phosphate buffer at pH 7.4 	ex 
= 340 nm 	em = 524 nm. 
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Figure 2.15. The plot for normalized fluorescence intensity to log [saccharide] in the 
presence of varying concentrations of D-fructose , D-galactose , D-
glucose  for compound 100 (3 x 10-5 M) in 0.1 M phosphate buffer at pH 
7.4 	ex = 340 nm and 	em = 524 nm. 
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Table 2.6. Calculated Kapp binding constants and r2 values for various saccharides of 
compound 100. 
 
Compound 
 
Carbohydrate 
100 
Kapp (M-1) r2 
D-Fructose 27.5 0.99 
D-Galactose 0.7 0.99 
D-Glucose 1.3 0.98 
 
 These results imply that binding ability of 2-naphthyl cahalcone boronic acids 
with carbohydrates is altered by changing the place of boronic acid substitution at the 
chalcone structure. Previously it was shown that binding constants of aryl boronic acids 
to carbohydrates increases in the presence of an electron withdrawing groups on the 
same phenyl ring (Mulla et al., 2004). 
 Boron atom has a special property because of its unfilled in neutral form. In such 
case boron atom behaves as a Lewis acid and electron deficient group. When the 
resonance structures of compound 99 and 100 are shown in figure 2.16. It can be seen 
that none of the resonance structures of compound 100 have a positive charge next to 
electron deficient boron atom. Resonance structures of compound 100 should be 
relatively less energetic compared to the resonance structures of compound 99 having a 
positive charge next to boron atom (99-b). Such resonance structure may force 
compound 99 to bind strongly to the carbohydrates. 
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Figure 2.16. Resonance structures of compound 99 and 100 
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2.3. Aromatase Inhibition Properties of Diboronic Acid Chalcone 
Compounds 
 
 Up to date in the best of our knowledge, there are not any reported boronic acid 
derivatized aromatase inhibitors. Because aromatase inhibitors are valuable for the fight 
with cancer, mono and diboronic acid chalcones (95-100) were tested for their 
aromatase inhibition properties. For this purpose, commercially available CYP19/MFC 
high throughput aromatase inhibition kit was used Ketoconazole (KTZ, figure 2.17) was 
used as a positive control for aromatase inhibition. Primary results showed that only 
three of the diboronic acid chalcones (95, 97 and 98) inhibit aromatase activity 50% at 
169 µM, 146 µM and 149 µM respectively. Percent aromatase inhibition values for 
KTZ, 95, 97 and 98 at different concentrations are given in figure 2.18. As shown in 
figures, all of the non linear regration analysis result r2 values higher than 0.9. On the 
other side, aromatase inhibition properties of other mono- and diboronic acid chalcones 
96, 99 and 100 could not be detected because of a possible contamination emitted a 
fluorescence that interferes with the fluorescence of the product of MFC. It is also 
possible that these chalcones may have an against activity on aromatase enzyme can 
lead the formation of higher amount of product. To clarify the subject more 
experimentation is necessary. 
 
 
 
Figure 2.17. Structure of KTZ. 
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Figure 2.18. Aromatase inhibition curves of diboronic acid chalcone derivatives (a) 95, 
(b) 97 and (c) 98 and (d) KTZ. 
 
2.4. Cytotoxic Properties of Diboronic Acid Chalcone Derivatives 
 
 Cytotoxic properties of chalcone boronic acids were examined in MCF-7 and 
PC3 cancer cell lines by MTT assay. As preliminary studies were shown in figure 2.23, 
compounds 96, 97 and 98 were found cytotoxic against MCF-7 cells equally with IC50 
values of 45 µM. On the other hand monoboronic acid derivatized naphthyl chalcones 
99 and 100 are found more cytotoxic. They inhibit MCF-7 cell proliferation 50% at 16.3 
µM and 14.3 µM respectively (Figure 2.19). 
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Figure 2.19. Cytotoxic activity profiles of diboronic acid chalcone derivatives against 
MCF-7 cancer cell lines (a) 96, (b) 97,(c) 98, (d) 99 and (e) 100. 
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 Similar trend was observed in PC3 cancer cells for mono and diboronic acid 
derivatized chalcones. 2-Naphthyl chalcone boronic acids are found more cytotoxic than 
disubstituted ones. Calculated IC50 values for compounds 96, 97, 99 and 100 are found 
45 µM, 47 µM, 31.2 µM and 22 µM respectively (Figure 2.20). 
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Figure 2.20. Cytotoxic activity profiles of diboronic acid chalcone derivatives against 
PC3 cancer cell lines (a) 96, (b) 97, (c) 99, (d) 100. 
 
 Cytotoxic activity of simple 2-naphthyl chalcone (Figure 2.21, 107) have 
previously reported by Brodie et al., that inhibited SVR cell proliferation 79% at 3µg/ml 
(11 µM) which is quite close to those of the monoboronic acid derivatized 2-naphthyl 
chalcones over MCF-7 (Brodie et al., 2005). Thus implies that boronic acid substitution 
did not help to improve the cytotoxic activity of the naphthyl chalcones against cancer 
cells. Additionally tests are underway to confirm the findings. 
50 
 

	
 
 
Figure 2.21. Structure of 2-naphthyl chalcone (107). 
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CHAPTER 3 
 
EXPERIMENTAL 
 
3.1. Chemistry 
 
3.1.1. General Methods 
 
 All reagents and solvents were commercially purchased from Sigma-Aldrich and 
Riedel (Extra pure grade), and were used as supplied. MERC TLC (Silica Gel 60 F 254) 
plates were used for monitoring reactions. Boronic acids were screened with UV lamp 
in 254 nm and 365 nm wavelength and 2% (w/v) solution of diphenylcarbazone ethanol 
in TLC. For chromatographic purification of the products were performed by flash 
column using 70-230 mesh sized silica gel. 
 1H NMR and 13C NMR spectra were acquired by Varian-400-MR (400 MHz) 
spectrometer. Data processed by ACD/NMR Processor Academic Edition Version: 
12.01. MeOD-d4 and DMSO-d6 were used as NMR solvent and chemical shifts reported 
in  (ppm). 
Carbohydrate binding studies were performed with Varian Cary Eclipse 
fluorescence spectrophotometer. UV-VIS absorption data carried out with Varian Cary 
50 Scan UV-Vis spectrophotometer. In all UV-VIS and fluorescence studies QS 1100 
quartz cuvettes were used. Ultra pure water was used for boronic acid carbohydrate 
binding studies purified with Milli-Q filtration system. pH adjusted with Inolab WTW 
pH 720 pH meter. 
MTT assay and aromatase inhibition assay were performed by Özgür Yılmazer 
ÇAKMAK and Burcu ALAÇAM. 
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3.1.5. Synthesis of Boronic Acid Chalcone Derivatives 
 
3.1.3.4. (E)-3-(3-boronic acid phenyl)-1-(3-boronic acid phenyl)prop-2-
en-1-one (95) 
 
 In a two neckled flask 218.17 mg of 3-acetylphenyl boronic acid (1.3 mmol, 1 
eq.) and 400 mg of 3-formylphenyl boronic acid (2.6 mmol, 2 eq.) were placed and 
dissolved in 7 mL of methanol and was stirred under reflux. Then 520 mg of NaOH (13 
mmol, 10 eq.) was directly added into mixture. After 4 hours, mixture was cooled down 
and acidified with 1M HCl to adjust pH 4 and then methanol was removed under 
reduced pressure. Crude product was extracted with ethyl acetate (3x60 mL) and the 
combined organic phase was dried over anhydrous MgSO4 and filtered with millipore 
system. After removal of solvent of the crude product, purification by column 
chromatography (MeOH/HOAc/DCM; 2:0.5:97.5 to 5:0.5:94.5) resulted desired 
product in 84% yield. 1H NMR (400 MHz, MeOD-d4)  = 8.46 (br. s., 1H), 7.65 - 8.17 
(m, 7H), 7.49 (t, J=7.24 Hz, 1H), 7.40 (t, J=7.24 Hz, 1H); 13C NMR (100 MHz, MeOD-
d4)  = 192.89, 146.65, 139.71, 138.58, 135.34, 135.05, 131.33, 129.37, 129.13, 122.91. 
 
3.1.3.3. (E)-3-(4-boronic acid phenyl)-1-(4-boronic acid phenyl)prop-2-
en-1-one (96) 
 
 In a two neckled flask 218.17 mg of 3-acetylphenyl boronic acid (1.34 mmol, 1 
eq.) and 400 mg of 3-formylphenyl boronic acid (2.66 mmol, 2 eq.) was placed and 
dissolved in 5 mL of methanol. Mixture was stirred under reflux until reagents were 
fully dissolved. After that; 520 mg of NaOH (13 mmol, 10 eq.) in 5 mL of methanol 
was added drop wise into reaction mixture. After 24 hours reflux, reaction mixture was 
cooled down and acidified with 1 M HCl to adjust pH 4, and then methanol was 
removed under reduced pressure. Crude product was extracted with ethyl acetate (3x60 
mL) and then the combined organic phase was dried over anhydrous MgSO4. Organic 
layer was filtered with millipore system, and removed under reduced pressure to yield 
crude product. Purification by column chromatography (MeOH/HOAc/DCM; 3:1:96) 
resulted desired product in 94% yield; 1H NMR (400 MHz, MeOD-d4)  = 7.97 (d, 
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J=8.20 Hz, 2H), 7.84 (d, J=6.65 Hz, 2H), 7.80-7.60 (m, 6H); 13C NMR (100 MHz, 
MeOD-d4)  = 192.67, 146.29, 140.27, 137.56, 135.51, 135.17, 128.84, 128.59, 123.48. 
 
3.1.3.5. (E)-3-(3-boronic acid phenyl)-1-(4-boronic acid phenyl)prop-2-
en-1-one (97) 
 
 Into a two neckled flask 400 mg of 3-formylphenyl boronic acid (2.6 mmol, 2 
eq.) and 218.17 mg of 4-acetylphenyl boronic acid (1.3 mmol, 1 eq.) were placed and 
solved in 3 mL of methanol under reflux. Then solution of 520 mg of NaOH (13 mmol, 
10 eq.) in 7 mL methanol was added into mixture drop wise. A day after reaction 
mixture was cooled down and acidified to adjust pH 4 with 1 M HCl. Afterwards 
methanol was evaporated, and remaining aqueous mixture extracted with ethyl acetate 
(3 x 60 mL). Organic layer was dried over MgSO4 and then removed under reduced 
pressure to yield crude product. Purification by column chromatography 
(MeOH/HOAc/DCM 3:1:9) resulted desired product in 34% yield. 1H NMR (400 MHz, 
MeOD-d4) = 8.06 (br. s., 1 H), 7.99 (d, J=7.83 Hz, 2 H), 7.85 (d, J=7.04 Hz, 2 H), 7.80 
- 7.66 (m, 4 H), 7.39 (t, J=7.43 Hz, 1 H); 13C NMR (100 MHz, MeOD-d4)  = 192.74, 
146.75, 135.39, 135.30, 135.15, 129.43, 128.59, 122.89. 
 
3.1.3.6. (E)-3-(4-boronic acid phenyl)-1-(3-boronic acid phenyl)prop-2-
en-1-one (98) 
 
 Into a two neckled flask 400 mg of 4-formylphenyl boronic acid (2.66 mmol 2 
eq) and 218.17 mg of 3-acetylphenyl boronic acid (1.3 mmol 1 eq) were placed and 
solved in 3 mL of methanol and stirred under reflux. Afterwards a solution of 520 mg of 
NaOH (13 mmol, 10 eq.) in 7 mL methanol was added drop wise into mixture. After 24 
hours reflux, reaction mixture cooled down and acidified to adjust pH 4 with 1 M HCl. 
Then methanol was evaporated under reduced pressure. Remaining aqueous mixture 
was extracted with ethyl acetate (3 x 60 mL). The combined organic layer was dried 
over MgSO4 and concentrated under reduced pressure to yield crude product. 
Purification by column chromatography (MeOH/HOAc/DCM; 1:1:98 to 4:1:95) 
resulted desired product in 44% yield. 1H NMR (400 MHz, MeOD-d4) = 1H NMR (400 
MHz, METHANOL-d4) δ ppm 8.41 (br. s., 1 H), 8.05 (dt, J=7.83, 1.56 Hz, 1 H), 7.99 - 
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7.89 (m, 1 H), 7.82 - 7. 59 (m, 6 H), 7.48 (t, J=7.43 Hz, 1 H); 13C NMR (100 MHz, 
MeOD-d4)  = 192.72, 146.13, 139.74, 138.52, 137.60, 135.49, 135.06, 131.23, 129.17, 
129.01, 128.82, 127.13, 123.52. 
 
 
3.1.3.1. (E)-1-(4-boronic acid phenyl)-3-(naphthalen-2-yl)prop-2-en-1-
one (99) 
 
 Into a two neckled flask 312.36 mg of 2-naphthaldehyde (2 mmol, 1 eq.) and 
327.94 mg of 4-acetylphenyl boronic acid (2 mmol, 1 eq.) were placed and solved in 5 
ml of methanol, and then stirred for 5 minutes under reflux. Afterwards 0.6 mL of 40% 
NaOH (6 mmol, 3 eq.) solution in water was added into reaction mixture drop wise. A 
day after, reaction mixture was cooled down and diluted with 1 M HCl to adjust pH 4. 
Methanol was evaporated under reduced pressure and remaining aqueous mixture was 
extracted with ethyl acetate (3x50 mL). The combined organic phase was dried over 
anhydrous MgSO4 and filtered with millipore system. Then filtered organic layer was 
concentrated under reduced pressure to yield crude product. Purification of the crude 
product by column chromatography (EtOH/DCM; 2:98), followed by recrystallization 
in ethyl acetate methanol mixture (10:1) yielded yellow crystals in 44% yield. 1H NMR 
(400 MHz, DMSO-d6)  = 8.40-8.29 (m, 2H), 8.26-8.05 (m, 4H), 8.03-7.87 (m, 5H), 
7.64-7.51 (m, 2H); 13C NMR (100 MHz, DMSO-d6)  = 189.36, 144.06, 138.69, 
134.40, 133.96 132.97, 132.36, 130.78, 128.57, 128.49, 127.75, 127.48, 127.40, 124.48, 
122.43. 
 
3.1.3.2. (E)-1-(3-boronic acid phenyl)-3-(naphthalen-2-yl)prop-2-en-1-
one (100) 
 
 To a refluxed solution of 95 mg of 2-naphthaldehyde (0.6 mmol, 2 eq.) in 4 mL 
methanol was added 3-acetylphenyl boronic acid (0.6 mmol, 1 eq.) and the mixture was 
stirred for 5 minutes under reflux. Then 3.6 mL of 40% NaOH (1.8 mmol, 3 eq.) 
solution in water was added into reaction mixture drop wise. After 24 hours, reaction 
mixture was cooled down and acidified with 1M HCl to adjust pH 4. Reaction solvent 
was evaporated under reduced pressure and remaining aqueous mixture was extracted 
with ethyl acetate (3x50 mL). Combined organic layer was dried over anhydrous 
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MgSO4 and filtered with millipore filtration system. Then organic phase was 
concentrated under reduced pressure to yield crude product. Purification by column 
chromatography (EtOH/DCM 2:98), followed by recrystallization in ethyl acetate 
methanol mixture (10:1) yielded yellow crystals in 41% yield. 1H NMR (400 MHz, 
DMSO-d6)  = 8.60 (s, 1 H), 8.38-8.28 (m, 3 H), 8.21 (d, J=7.83 Hz, 1 H), 8.14 – 7.87 
(m, 7 H), 7.64 - 7.52 (m, 3 H); 13C NMR (100 MHz, DMSO-d6)  = 189.48, 143.79, 
138.77, 136.80, 134.10, 133.90, 132.95, 132.32, 130.61, 130.11, 128.49, 127.71, 
127.43, 126.80, 124.26, 122.50. MS (EI, m/z): 257.2 ([M-B(OH)2]+) [Calculated: 
302,11 for C19H15BO3]. 
 
3.1.2. Carbohydrate Binding 
 
 All carbohydrate binding studies were carried out as following procedure; 3.30 x 
10-5 M solution of boronic acid chalcone derivative in 0.1 M sodium phosphate 
monobasic buffer having 1% DMSO were prepared and then pH was adjusted to 7.4 ± 
0.01 with 5 M NaOH. To prepare 1% DMSO buffer solution, 6.60 x 10-3 M of chalcone 
boronic acid derivative was prepared with 10 mL DMSO and then 5 mL of this stock 
solution was added into 500 mL of 0.1 M sodium phosphate monobasic buffer. Then pH 
was adjusted with 5 M NaOH if necessary (stock 1). To alternate carbohydrate 
concentrations a 200 mM stock carbohydrate solution (stock 2) was prepared by using 
stock 1. Stock 2 was stored in room temperature for 15 minutes to be sure for the 
binding of boronic acid to carbohydrates. Then stock 2 was diluted into 50 mL falcon 
tubes to form 9 different carbohydrate concentrations between 0,1 mM and 100 mM 
(0.1 mM, 1 mM, 2,5 mM, 5 mM, 10 mM, 20 mM, 25 mM, 50 mM, 100 mM) with stock 
1. After 15 minutes fluorescence measurements were carried out with 3 mL of solutions 
in quartz cuvettes. All measurements were done in 3 replicates. Samples were excited 
between 315 nm and 340 nm. Binding constants of boronic acids with carbohydrates 
were calculated by Benesi-Hildebrand method, by assuming 1:1 binding of boronic 
acids with carbohydrates. 
 
 
56 
 
3.1.3. MTT Assay 
 
 Human Prostat Cancer (PC-3) cell line was kindly provided by Associate 
Professor Kemal Sami Korkmaz (Ege University, Engineering Faculty, Department of 
Bioengineering), human breast cancer (MCF-7) cell line was obtained from ap 
Institute. PC3 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 5% fetal bovine serum (FBS), 1 µg/mL streptomycin/100 IU/mL penicillin, 
MCF7 cell line was maintained in Roswell Park Memorial Institude-1640 (RPMI-1640) 
containing 15% FBS (BIO-IND), 1 µg/mL streptomycin/100 IU/mL penicillin 
incubated at 37 ºC in the dark with 5% CO2 humidified incubator and passaged when 
they reached 80-85% confluency. Cells used in experiments were maintained from 10-
20th passages. 
 To investigate the cytotoxic activity of the compounds, 95 µL of cell suspension 
was inoculated into 96-well microculture plates at 1x104 cells density per well in culture 
media containing FBS, penicillin/streptomycin. Compounds were dissolved in dimethyl 
sulfoxide (DMSO) (Sigma Chemical Co.), filter sterilized, diluted at the appropriate 
concentrations with the culture medium. In all well, 1% DMSO concentration was 
fixed. Dilutions of compounds were freshly prepared before each experiment. After 24h 
cultivation for cell attachment, compounds were added at final concentration 50.0, 40.0, 
30.0, 20.0, 10.0, 1.0, and 0.5 µM for triplicate assay. Cells were treated with the 
compounds for 48 hours and cytotoxic effects were determined by tetrazolium (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma Chemical Co.) based 
colorimetric assay. This method depends on the cleavage of tetrazolium salt to purple 
formazan crystals by mitochondrial enzymes of metabolically active cells (Ciapetti, et 
al. 1993). Briefly, 4 hours before the end of incubation period, medium of the cells was 
removed and wells were washed by pre-warmed phosphate-buffered saline (PBS) to 
remove any trace of compounds and to prevent color interference while optical density 
determination. MTT stock solution (5 mg/mL) was diluted at 1:10 ratio into complete 
culture media, 100 µL of MTT dilution was added into each well and incubated. After 
3.5 hours plates were centrifuged at 1800 rpm for 10 minute at room temperatures to 
avoid accidental removal of formazan crystals. Crystals were dissolved with 100 µL 
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DMSO. The absorbance was determined at 540 nm. Results were represented as 
percentage cell viability. 
 
3.1.4. Aromatase Inhibition Assay 
 
 CYP19/MFC high-throughput screening kit (BD Biosciences, Oxford, UK) was 
used for aromatase inhibition assays. According to the manufacturer’s protocol, amount 
of the conversion of 7-methoxy-4-trifluoromethyl coumarin (MFC) substrate into 
fluorescencent 7-hydroxy-4-trifluoromethyl coumarin (HFC) product was measured in 
the presence of varying concentrations of compounds to be tested in acetonitrile 
solutions in 96-well plates. Fluorescence of HFC was detected by employing an 
excitation wavelength of 405 nm and emission wavelength of 520 nm. Concentrations 
of CYP19 and substrate were fixed to 7.5 nM and 25 M respectively. Potential 
aromatase inhibitors were applied at 1200.00, 400.00, 133.33, 44.44, 14.81, 4.94, 1.65, 
and 0.55 µM concentrations. Ketoconazole (KTZ) was used as a positive standard. 
Background fluorescence was subtracted from the fluorescence of the all reactions to 
find the fluorescence emitted only from HFC products. All reactions were carried out in 
a parallel duplicate.  
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CHAPTER 4 
 
CONCLUSION 
 
 Boronic acid chalcone molecules are selective anticancer drug candidates and 
fluorescent probes for saccharide detection. In this study, mono- and diboronic acid 
chalcone derivatives were designed and synthesized to increase the cytotoxic activity of 
the chalcone boronic acid derivatives against cancer cells. First time in literature, 
synthesized boronic acid chalcone derivatives were tested for possible aromatase 
inhibition properties, besides their cytotoxic activity. In addition binding studies of 
boronic acid chalcone derivatives with various carbohydrates were performed at 
physiological pH. 
 Compounds are synthesized via Claisen-Schmidt condensation reaction in the 
presence of an excess amount of strong base in methanol. Synthesis of diboronic acid 
chalcone analogues and 2-naphtyl chalcone boronic acid derivatives were successfully 
accomplished except ortho substituted (2,3’- and 2,4’-) diboronic acid chalcone 
derivatives. 
 Diboronic acid chalcone derivatives were tested to show their aromatase 
inhibition and cytotoxic properties against MCF-7 and PC3 cell lines. Our investigation 
showed that addition of a second boronic acid moiety to chalcone structure did not 
cause an increase in the cytotoxic activity of boronic acid chalcone derivatives against 
cancer cell lines. Unexpectedly, cytotoxic activities of diboronic acid chalcones are 
lower than those of boronic acid modified chalcones in literature. Boronic acid 
derivatized 2-naphthyl chalcones are cytotoxic against both cancer cell lines MCF-7 and 
PC3. They were found more cytotoxic compared to diboronic acid derivatives. 
However, comparison of their IC50 values with those of unsubstituted 2-naphthyl 
boronic acid chalcones implies that boronic acid substitution does not have any effect 
on the cytotoxic profiles of 2-naphthyl chalcones. 
 Additionally, even three of the diboronic acid functionalized chalcones show 
aromatase inhibition activity, IC50 values of those are much more higher compared to 
the known flavonoids showing aromatase inhibition in literature  
59 
 
 Finally, carbohydrate binding studies resulted that diboronic acid chalcones 
cannot be used at physiological pH to detect carbohydrate because of the lack of their 
fluorescence responses in carbohydrate solutions. On the other hand fluorescence 
responses of 2-naphthyl chalcone boronic acids proportionally increase with the 
concentration of carbohydrates especially in D-fructose as expected. 
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APPENDIX A 
 
1H NMR AND 13C NMR SPECTRUM OF COMPOUNDS 96 
AND 100 
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Figure A.1. 1H NMR spectrum of (E)-3-(4- boronic acid phenyl)-1-(4- boronic acid phenyl)prop-2-en-1-one (96). 
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Figure A.2. 13C NMR spectrum of (E)-3-(4- boronic acid phenyl)-1-(4- boronic acid phenyl)prop-2-en-1-one (96). 
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Figure A.3. 1H NMR spectrum of (E)-1-(4- boronic acid phenyl)-3-(naphthalen-2-yl)prop-2-en-1-one (99) 
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Figure A.4. 13C NMR spectrum of (E)-1-(4- boronic acid phenyl)-3-(naphthalen-2-yl)prop-2-en-1-one (99) 
